Form 4: MicroVision Director Carlile's RSU Vesting & Correction
Insider Transaction Report
MicroVision Director Robert Paul Carlile reported the vesting of 22,007 restricted stock units into common stock, along with a correction to a prior RSU grant amount.
Summary
- Director Robert Paul Carlile acquired 22,007 shares of MicroVision, Inc. common stock through the vesting of restricted stock units (RSUs).
- The transaction occurred on September 2, 2025, with a conversion price of $0.00 per share.
- Following this transaction, Carlile beneficially owns 306,785 shares of common stock directly.
- The vesting was part of RSUs granted on June 6, 2025, which are scheduled to vest in four equal quarterly installments.
- A previous Form 4 filed on June 6, 2025, incorrectly reported the total RSUs granted on June 5, 2025, as 87,462 RSUs; the correct amount was 88,208 RSUs, and the current vesting was calculated based on 88,028 RSUs.
Sentiment
Score: 6
Explanation: The filing reports a routine, expected insider transaction (RSU vesting) and a minor correction to a previous filing. It is neutral to slightly positive as it reflects ongoing director compensation and transparency in reporting, without indicating any operational or financial issues.
Positives
- The vesting of restricted stock units indicates continued compensation for the director, aligning their interests with shareholders.
- The correction of a prior reporting error demonstrates transparency in disclosure.
Future Outlook
The RSUs granted on June 6, 2025, are scheduled to vest in four equal quarterly installments until fully vested on the earlier of the first anniversary of the grant date or the day prior to the Issuer's 2026 Annual Meeting of Stockholders, contingent on continued service as a director.
Industry Context
This filing is a routine insider transaction report and does not provide broader industry context.
Comparison to Industry Standards
- This filing reports a standard RSU vesting event for a director, which is a common form of equity compensation across publicly traded companies. No specific comparable companies or projects are mentioned.
Stakeholder Impact
- Shareholders: The increase in common stock held by a director aligns their interests with shareholders. The vesting itself represents a minor dilution from the existing equity compensation pool.
Next Steps
- Future quarterly installments of the RSUs granted on June 6, 2025, are scheduled to vest.
- The RSUs will be fully vested on the earlier of the first anniversary of the grant date or the day prior to the Issuer's 2026 Annual Meeting of Stockholders, provided continued director service.
Key Dates
| Date | Description |
|---|---|
| 06/05/2025 | Original grant date for RSUs, incorrectly reported in a prior Form 4. |
| 06/06/2025 | Date RSUs were granted and date of the incorrect Form 4 filing. |
| 09/02/2025 | Transaction date for the vesting and distribution of 22,007 RSUs into common stock. |
| 09/02/2025 | Date exercisable and expiration date for the derivative securities (RSUs). |
| 09/03/2025 | Signature date of the reporting person's attorney-in-fact for this Form 4. |
| 2026 Annual Meeting of Stockholders | Latest potential full vesting date for RSUs, if earlier than the first anniversary of the grant date. |
Recommendation
holdThis Form 4 reports a routine, pre-scheduled vesting of restricted stock units for a director and a minor correction to a previous filing. It does not contain any new material information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The transaction is an expected part of executive compensation and does not indicate a significant positive or negative shift in the company's outlook.
Keywords
MicroVision, MVIS, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Director Compensation, Beneficial Ownership, Equity Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.